How the CDSCO Approval Process Works for Generic Medicines in India: A 2026 Guide

India is known as the “Pharmacy of the World,” supplying over 20% of the global generic medicine market by volume. But before any generic medicine reaches a pharmacy shelf — whether in Mumbai or Manhattan — it must undergo rigorous scrutiny by the Central Drugs Standard Control Organization (CDSCO). Understanding this approval process is essential for international buyers, healthcare professionals, and patients who want to verify the quality and safety of Indian generics.

What Is the CDSCO?

The Central Drugs Standard Control Organization (CDSCO) is India’s national regulatory authority for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health and Family Welfare, the CDSCO is the Indian equivalent of the U.S. FDA (Food and Drug Administration) or the European Medicines Agency (EMA).

Key responsibilities of CDSCO include:

Approval of new drugs and clinical trials
Setting standards for drug manufacturing, import, and sale
Licensing of drug manufacturing and import units
Monitoring adverse drug reactions (pharmacovigilance)
Enforcing the Drugs and Cosmetics Act, 1940 and its rules

Source: CDSCO official website (cdsco.gov.in) and the Drugs and Cosmetics Act, 1940.

Generic vs. Branded Drugs: What CDSCO Checks

A generic medicine is a pharmaceutical product that is bioequivalent to an already-approved brand-name drug. It contains the same active ingredients, strength, dosage form, and route of administration. The key difference is that generics are sold under their chemical name or a different brand name, typically at a fraction of the cost.

For a generic drug to gain CDSCO approval, the manufacturer must prove:

Bioequivalence: The generic delivers the same amount of active ingredient into the bloodstream at the same rate as the innovator drug
Quality: Manufacturing follows Good Manufacturing Practices (GMP) as per Schedule M of the Drugs and Cosmetics Rules
Safety: No new or unexpected adverse effects compared to the reference product
Stability: The drug maintains its potency throughout its shelf life under specified storage conditions

Step-by-Step CDSCO Approval Pathway (2026)

Step 1: Pre-submission and Formulation Development

Before filing, the manufacturer develops a formulation that matches the reference listed drug (RLD). This includes selecting appropriate excipients, determining the manufacturing process, and conducting preliminary stability studies. The manufacturer also identifies a CDSCO-approved bioequivalence study center to conduct comparative testing.

Step 2: Submission of Application (Form 44)

The manufacturer submits an application in Form 44 under the Drugs and Cosmetics Rules, 1945, along with:

Formulation and manufacturing details
Bioequivalence study report
Stability data (accelerated and real-time)
Certificate of Pharmaceutical Product (COPP) from the exporting country (if applicable)
Manufacturing license and WHO-GMP certificate
Draft product labelling and packaging inserts

Step 3: Review by CDSCO Subject Expert Committee (SEC)

The application is reviewed by the CDSCO’s Subject Expert Committee (SEC), a panel of pharmacologists, toxicologists, and medical experts. The SEC evaluates the bioequivalence data, manufacturing quality, and safety profile. The committee may request additional studies or clarifications before recommending approval.

Step 4: Lab Testing (Recent 2026 Reform)

In a major reform announced in February 2026, CDSCO revised its drug testing norms to allow immediate laboratory testing of samples as soon as applications are filed, rather than waiting for the full administrative review to be completed. Effective June 1, 2026, manufacturers can now receive an immediate No Objection Certificate (NOC) for testing at CDSCO’s network of labs — including the Indian Pharmacopoeia Commission (IPC) in Ghaziabad, and central labs in Mumbai, Kasauli, and Noida.

This reform is expected to cut approval timelines significantly by shifting the sequential process into a more parallel workflow. It was widely reported by Business Standard, CNBC TV18, and Medical Dialogues in February 2026.

Step 5: Approval and Manufacturing License

Once the SEC recommends approval and lab testing is cleared, CDSCO grants the Form 46 (license to manufacture) or Form 45/45A (license to import). The product is then listed in the CDSCO’s approved drug database. The manufacturer can now begin commercial production, subject to ongoing regulatory oversight.

Major Regulatory Reforms in 2025-2026

India’s drug regulatory framework has seen significant modernization in recent months:

NDCT Rules 2026 Amendments (January 2026): The government notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, halving the statutory processing timeline for test licenses from 90 days to 45 days (Source: The New Indian Express, January 2026).
Prior Intimation System (April 2026): CDSCO introduced a “Prior Intimation” system to fast-track approvals for certain categories of drugs, allowing manufacturers to proceed with notified changes without waiting for prior approval (Source: BW Healthcare World, April 2026).
Immediate Lab Testing NOC (June 1, 2026): As discussed above, manufacturers can now begin lab testing immediately upon filing (Source: Business Standard, February 2026).
WHO-GMP Compliance Push: Pharmexcil in collaboration with CDSCO is actively strengthening WHO-GMP compliance across small and medium pharmaceutical enterprises (MSMEs) to enhance export quality standards (Source: ETPharma/Pharmexcil AGM, December 2025).

How International Buyers Can Verify CDSCO Approval

For buyers importing Indian generic medicines, verifying CDSCO approval status is a critical due diligence step. Here’s a practical checklist:

Check the CDSCO online database: Visit cdsco.gov.in and search the “Drugs Approved” portal by brand name, active ingredient, or manufacturer
Request the COPP: The Certificate of Pharmaceutical Product is issued by the state drug controller and should match the product’s manufacturing license
Verify WHO-GMP certification: Check if the manufacturing site holds current WHO-GMP certification, which is a prerequisite for export
Review bioequivalence data: Reputable manufacturers will provide bioequivalence study summaries upon request
Work with verified distributors: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA member directory. IMSDA members must maintain valid CDSCO-compliant manufacturing and import licenses as a condition of membership.

CDSCO vs. FDA vs. EMA: How They Compare

While CDSCO, FDA, and EMA all regulate drug safety, there are notable differences:

Approval Timeline: CDSCO approval typically takes 12–24 months for generics. FDA averages 10–15 months (ANDA pathway). EMA varies by country but averages 12–18 months for generics via the decentralized procedure.
Inspection Frequency: FDA conducts routine inspections every 2 years; CDSCO inspections are more variable depending on state-level drug control infrastructure.
Cost: Filing a generic drug application with CDSCO costs significantly less than an FDA ANDA or EMA DCP application, which is one reason India has become a global hub for generic manufacturing.
Mutual Recognition: India has mutual recognition agreements for GMP with several countries, but not with the US or EU. However, many Indian manufacturers hold both WHO-GMP certification and USFDA/EMA approvals.

Common Pitfalls to Avoid

Assuming all CDSCO-approved drugs are automatically WHO-GMP certified — they are not. WHO-GMP is a separate certification, though increasingly aligned
Confusing state-level drug licensing with central CDSCO approval — state drug controllers issue manufacturing licenses, while CDSCO handles new drug approvals and import licenses
Skipping the COPP verification — a missing or expired COPP can lead to customs delays in the destination country
Not checking the NDCT Rules 2026 amendments — the shortened timelines and new prior intimation system change how approvals work in practice

Final Thoughts

The CDSCO approval process is the foundation of India’s reputation as a reliable supplier of high-quality generic medicines. With the 2025–2026 regulatory reforms — including the NDCT amendments, the prior intimation system, and the immediate lab testing NOC — the process is becoming faster and more efficient while maintaining rigorous safety and quality standards.

For international buyers, understanding this process is not just about regulatory compliance — it is about patient safety. Partnering with IMSDA member distributors ensures you are working with verified suppliers who adhere to CDSCO regulations and maintain valid manufacturing and import licenses.

For more information, contact IMSDA at contact@indiamedicine.org.